Literature DB >> 26681122

Current risks of HeartMate II pump thrombosis: Non-parametric analysis of Interagency Registry for Mechanically Assisted Circulatory Support data.

Nicholas G Smedira1, Eugene H Blackstone2, John Ehrlinger3, Lucy Thuita3, Christopher D Pierce4, Nader Moazami5, Randall C Starling6.   

Abstract

BACKGROUND: Data from 3 institutions revealed an abrupt increase in HeartMate II (Thoratec) pump thrombosis starting in 2011, associated with 48% mortality at 6 months without transplantation or pump exchange. We sought to discover if the increase occurred nationwide in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) data, and if so (1) determine if accelerated risk continued, (2) identify predictors, (3) investigate institutional variability, and (4) assess mortality after pump thrombosis.
METHODS: From April 2008 to June 2014, 11,123 HeartMate II devices were implanted at 146 institutions. Machine learning, non-parametric Random Forests for Survival was used to explore risk-adjusted thrombosis based on 87 pre-implant and implant variables, including implant date.
RESULTS: A total of 995 pumps thrombosed, with risk peaking within weeks of implant. The risk-adjusted increase in pump thrombosis began in 2010, reached a maximum in 2012, and then plateaued at a level that was 3.3-times higher than pre-2010. Pump exchange, younger age, and larger body mass index were important predictors, and institutional variability was largely explained by implant date, patient profile, and duration of support. The probability of death within 3 months after pump thrombosis was 24%.
CONCLUSIONS: Accelerated risk of HeartMate II thrombosis was confirmed by Interagency Registry for Mechanically Assisted Circulatory Support data, with risk subsequently leveling at a risk-adjusted rate higher than observed pre-2010. This elevated thrombosis risk emphasizes the need for improved mechanical circulatory support systems and post-market surveillance of adverse events. Clinicians cognizant of these new data should incorporate them into their and their patients' expectations and understanding of risks relative to those of transplantation and continued medical therapy.
Copyright © 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HeartMate II; INTERMACS; left ventricular assist device (LVAD); mortality; pump thrombosis; regulatory

Mesh:

Year:  2015        PMID: 26681122     DOI: 10.1016/j.healun.2015.10.027

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Continuously Updated Estimation of Heart Transplant Waitlist Mortality.

Authors:  Eugene H Blackstone; Jeevanantham Rajeswaran; Vincent B Cruz; Eileen M Hsich; Marijan Koprivanac; Nicholas G Smedira; Katherine J Hoercher; Lucy Thuita; Randall C Starling
Journal:  J Am Coll Cardiol       Date:  2018-08-07       Impact factor: 24.094

2.  Clinical Relevance of Histopathologic Analysis of HeartMate II Thrombi.

Authors:  Lisa Baumann Kreuziger; Mark S Slaughter; Kartik Sundareswaran; Alan E Mast
Journal:  ASAIO J       Date:  2018 Nov/Dec       Impact factor: 2.872

3.  Clinical research challenges in the era of cardiovascular medical devices.

Authors:  Jan W Borowiec
Journal:  Kardiochir Torakochirurgia Pol       Date:  2016-09-30

4.  Device Thrombogenicity Emulation: An In Silico Predictor of In Vitro and In Vivo Ventricular Assist Device Thrombogenicity.

Authors:  Wei Che Chiu; Phat L Tran; Zain Khalpey; Eric Lee; Yi-Ren Woo; Marvin J Slepian; Danny Bluestein
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

5.  Dynamic prediction of left ventricular assist device pump thrombosis based on lactate dehydrogenase trends.

Authors:  Thomas E Hurst; Andrew Xanthopoulos; John Ehrlinger; Jeevanantham Rajeswaran; Amol Pande; Lucy Thuita; Nicholas G Smedira; Nader Moazami; Eugene H Blackstone; Randall C Starling
Journal:  ESC Heart Fail       Date:  2019-07-18

6.  Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.

Authors:  Andrew Xanthopoulos; Konstantinos Tryposkiadis; Filippos Triposkiadis; Kiyotaka Fukamachi; Edward G Soltesz; James B Young; Kathy Wolski; Eugene H Blackstone; Randall C Starling
Journal:  J Am Heart Assoc       Date:  2020-07-10       Impact factor: 5.501

7.  Validation of Intrinsic Left Ventricular Assist Device Data Tracking Algorithm for Early Recognition of Centrifugal Flow Pump Thrombosis.

Authors:  Christoph Gross; Kamen Dimitrov; Julia Riebandt; Dominik Wiedemann; Günther Laufer; Heinrich Schima; Francesco Moscato; Michael C Brown; Abhijit Kadrolkar; Robert W Stadler; Daniel Zimpfer; Thomas Schlöglhofer
Journal:  Life (Basel)       Date:  2022-04-09

8.  Left ventricular assist device exchange for the treatment of HeartMate II pump thrombosis.

Authors:  Jasmin S Hanke; Günes Dogan; Leonard Wert; Marcel Ricklefs; Jan Heimeshoff; Anamika Chatterjee; Christina Feldmann; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 9.  Left Ventricular Assist Device Management in the Emergency Department.

Authors:  Paul Trinquero; Andrew Pirotte; Lauren P Gallagher; Kimberly M Iwaki; Christopher Beach; Jane E Wilcox
Journal:  West J Emerg Med       Date:  2018-07-26

10.  Understanding and Addressing Variation in Health Care-Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study.

Authors:  Min Zhang; P Paul Chandanabhumma; Michael D Fetters; Francis D Pagani; Preeti N Malani; John M Hollingsworth; Russell J Funk; Keith D Aaronson; Robert L Kormos; Carol E Chenoweth; Supriya Shore; Tessa M F Watt; Lourdes Cabrera; Donald S Likosky
Journal:  JMIR Res Protoc       Date:  2020-01-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.